Cardiovascular Systems, Inc. (CSII) to Release Quarterly Earnings on Tuesday
Cardiovascular Systems, Inc. (NASDAQ:CSII) is scheduled to be announcing its earnings results after the market closes on Tuesday, October 24th.
Cardiovascular Systems (NASDAQ:CSII) last issued its quarterly earnings results on Wednesday, August 2nd. The medical device company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.05) by $0.07. The firm had revenue of $52.90 million for the quarter, compared to analysts’ expectations of $51.98 million. Cardiovascular Systems had a negative net margin of 0.87% and a positive return on equity of 0.88%. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.15) EPS. On average, analysts expect Cardiovascular Systems to post $0.01 EPS for the current fiscal year and $0.18 EPS for the next fiscal year.
Cardiovascular Systems, Inc. (NASDAQ:CSII) opened at 27.12 on Tuesday. The stock’s 50 day moving average is $28.99 and its 200 day moving average is $30.29. Cardiovascular Systems, Inc. has a 1-year low of $21.29 and a 1-year high of $33.11. The firm’s market capitalization is $894.72 million.
A number of analysts recently issued reports on CSII shares. Needham & Company LLC restated a “buy” rating and set a $37.00 price objective (up previously from $32.00) on shares of Cardiovascular Systems in a report on Friday, July 14th. Bank of America Corporation downgraded shares of Cardiovascular Systems from a “neutral” rating to an “underperform” rating in a report on Wednesday, June 21st. BidaskClub downgraded shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Raymond James Financial, Inc. began coverage on shares of Cardiovascular Systems in a research note on Friday, September 22nd. They issued a “market perform” rating for the company. Finally, Citigroup Inc. began coverage on shares of Cardiovascular Systems in a research note on Thursday, September 21st. They issued a “market perform” rating for the company. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $34.25.
In other Cardiovascular Systems news, CEO Scott R. Ward sold 5,529 shares of Cardiovascular Systems stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $30.41, for a total transaction of $168,136.89. Following the completion of the sale, the chief executive officer now directly owns 282,536 shares in the company, valued at $8,591,919.76. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Edward M. Brown sold 13,031 shares of Cardiovascular Systems stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $29.09, for a total transaction of $379,071.79. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 51,065 shares of company stock valued at $1,514,031. 3.30% of the stock is owned by corporate insiders.
About Cardiovascular Systems
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.